Merck lifts full-year forecast as Keytruda sales soar
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Merck (MRK) PT Raised to $120 at Cantor Fitzgerald
October 27, 2022 12:47 PM EDTCantor Fitzgerald analyst Louise Chen raised the price target on Merck (NYSE: MRK) to $120.00 (from $107.00) while maintaining an Overweight rating.
The analyst commented, ". Post a 3Q22 sales and EPS beat relative to FactSet consensus, we are reiterating our Overweight (OW) rating. We are... More
